ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2583

Effects of Mycophenolate Mofetil (MMF) on Immunogenicity of Ppsv-23 Vaccine in Patients with Systemic Lupus Erythematosus and Other Autoimmune Diseases

Priya Prakash1, Mark Tratenberg2, Slavica Bobic3, Rui Zhang4, Kirk Sperber5, Amy Wasserman6 and Julia Ash7, 1Medicine-Rheumatology, New York Medical College / Westchester Medical Center, Valhalla, NY, 2New York Medical College / Westchester Medical Center, valhalla, NY, 3Medicine-Rheumatology, New York Medical College / Westchester Medical Center, valhalla, NY, 4Medicine -Rheumatology, New York Medical College / Westchester Medical Center, valhalla, NY, 5New York Medical College / Westchester Medical Center, Valhalla, NY, 6Medicine - Rheumatology, New York Medical College / Westchester Medical Center, VALHALLA, NY, 7Medicine -Rheumatology, New York Medical College / Westchester Medical Center, Valhalla, NY

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Autoimmunity, mycophenolate mofetil, rheumatologic disease and vaccines, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: MMF suppresses immune function by inhibiting T cell dependent and independent humoral immune responses. This study investigates the humoral immune response to the PPSV23 vaccine by MMF in a larger sample size.   Furthermore, this study explores the effect of MMF dose and concurrent steroid use on the anti-pneumococcal antibody responses.

Methods: In this observational cross-sectional study, patients treated with immune suppressive medications who had received PPVS23 were identified and stratified based on receiving MMF or non-MMF immunosuppressants (control group). The humoral response was assessed in both groups using serum IgG titers against 14 pneumococcal polysaccharides (ELISA) as a surrogate marker. The stimulation index (SI) was calculated by dividing the post by the pre immunization titer, which was compared between the MMF and non-MMF groups .The primary endpoints of the study were protective titers of >1.3 µg/ml or either a 4-fold, 3-fold, or 2-fold increase in the SI for 70% of the 14 pneumococcal polysaccharides.

Results: The total study subjects included 39 patients .The MMF group included 23 patients: 21 with SLE, 1 with uveitis, and 1 with DM. The control group included 16 patients: 12 with SLE, 2 with RA, 1 with uveitis, and 1 with PsA. The humoral responses in the MMF group were significantly lower compared to the control group. 40 % of patients in the MMF group vs. 60 % of the control group had protective antibody levels (> 1.3 ug/ml). However, statistically significant differences were only observed in serotypes 51 and 4 (p = 0.05 & p = 0.025). Suppressed antibody responses were observed in the MMF group as defined by a lack of a 4-fold (p = 0.0001), 3-fold (p = 0.001), and 2-fold (p = 0.0163) increase in the SI vs. the control group. 20 %(n=3) of the study group and 50% (n=8) in the control group had more than a 2-fold increase in post-immunization antibody titers to 10 of the 14 serotypes. Patients receiving more than 1.5 g of MMF daily had more suppressed antibody responses defined as a lack of a 4-fold increase (p = 0.04) in the SI compared to patients taking less than 1.5 g of MMF daily. Patients in both the MMF and control groups received less than 10 mg of prednisone that had no effect on the anti-pneumococcal antibody responses.

Conclusion: This data suggests that humoral responses to pneumococcal polysaccharides are more blunted in patients receiving MMF compared to other immunosuppressants. There was a dose effect of MMF on the humoral response. However, no effect of steroids was observed.  Evaluation of post-vaccination humoral immunity should be considered in patients receiving MMF.


Disclosure: P. Prakash, None; M. Tratenberg, None; S. Bobic, None; R. Zhang, None; K. Sperber, None; A. Wasserman, None; J. Ash, None.

To cite this abstract in AMA style:

Prakash P, Tratenberg M, Bobic S, Zhang R, Sperber K, Wasserman A, Ash J. Effects of Mycophenolate Mofetil (MMF) on Immunogenicity of Ppsv-23 Vaccine in Patients with Systemic Lupus Erythematosus and Other Autoimmune Diseases [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/effects-of-mycophenolate-mofetil-mmf-on-immunogenicity-of-ppsv-23-vaccine-in-patients-with-systemic-lupus-erythematosus-and-other-autoimmune-diseases/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effects-of-mycophenolate-mofetil-mmf-on-immunogenicity-of-ppsv-23-vaccine-in-patients-with-systemic-lupus-erythematosus-and-other-autoimmune-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology